Crescent Biopharma (CBIO) Receivables - Other (2016 - 2025)
Crescent Biopharma (CBIO) has disclosed Receivables - Other for 11 consecutive years, with $78762.0 as the latest value for Q1 2025.
- On a quarterly basis, Receivables - Other fell 28.36% to $78762.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $78762.0, a 28.36% decrease, with the full-year FY2023 number at $175820.0, up 22.08% from a year prior.
- Receivables - Other was $78762.0 for Q1 2025 at Crescent Biopharma, up from $50255.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $444568.0 in Q1 2021 to a low of $1347.0 in Q4 2021.
- A 5-year average of $121182.9 and a median of $100138.5 in 2022 define the central range for Receivables - Other.
- Biggest YoY gain for Receivables - Other was 10591.61% in 2022; the steepest drop was 98.93% in 2022.
- Crescent Biopharma's Receivables - Other stood at $1347.0 in 2021, then surged by 10591.61% to $144016.0 in 2022, then rose by 22.08% to $175820.0 in 2023, then tumbled by 71.42% to $50255.0 in 2024, then skyrocketed by 56.72% to $78762.0 in 2025.
- Per Business Quant, the three most recent readings for CBIO's Receivables - Other are $78762.0 (Q1 2025), $50255.0 (Q3 2024), and $76710.0 (Q2 2024).